A new, affordable injectable HIV prevention drug, lenacapavir, offers a significant breakthrough in global health.
Costing only $40 annually, this twice-yearly injection will be available in 120 low- and middle-income countries starting in 2027.
This groundbreaking medicine, highly effective in clinical trials, provides a transformative opportunity to curb the HIV epidemic.
The initiative, spearheaded by collaborations between various organizations, promises a genuine chance to significantly reduce new HIV infections worldwide.
